603229.SH
奥翔药业
SSE · Healthcare · Biotechnology · CN
CNY 7.94
−1.98%Aug 28, 2026, 08:43 UTC
Aoxiang Pharmaceutical announced its first-half 2026 results with revenue of 468 million yuan, down 2.96% year-on-year, and net profit attributable to shareholders of 120 million yuan, down 29.23% year-on-year.
Source:Aug 21, 2026, 09:11 UTC
Aoxiang Pharmaceutical's wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical received drug registration certificates from China's National Medical Products Administration for ruxolitinib phosphate tablets in 5mg, 15mg, and 20mg strengths, deemed equivalent to passing generic consistency evaluation.
Source: